Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

NCT00215995 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer
Gastric Cancer

Interventions

DRUG: Cisplatin
DRUG: Irinotecan
DRUG: ZD 1839

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]